United Therapeutics (NASDAQ:UTHR) Director Tommy Thompson Sells 910 Shares

United Therapeutics Corporation (NASDAQ:UTHR) Director Tommy Thompson sold 910 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $500.59, for a total transaction of $455,536.90. Following the transaction, the director directly owned 8,480 shares of the company’s stock, valued at approximately $4,245,003.20. This represents a 9.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

United Therapeutics Trading Up 2.0%

United Therapeutics stock opened at $517.13 on Friday. The firm’s 50 day simple moving average is $463.63 and its 200 day simple moving average is $380.56. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $518.61. The firm has a market capitalization of $22.27 billion, a PE ratio of 19.60, a price-to-earnings-growth ratio of 5.03 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. The firm had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business’s quarterly revenue was up 6.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.39 earnings per share. Research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on UTHR. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a report on Monday, December 8th. Morgan Stanley set a $447.00 price objective on United Therapeutics in a report on Wednesday, October 29th. Bank of America increased their target price on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a report on Tuesday, September 2nd. Jefferies Financial Group reaffirmed a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Finally, HC Wainwright increased their price objective on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $505.00.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB increased its position in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares in the last quarter. Chung Wu Investment Group LLC purchased a new stake in United Therapeutics during the 2nd quarter valued at about $29,000. Abich Financial Wealth Management LLC bought a new stake in United Therapeutics during the 3rd quarter valued at about $44,000. SVB Wealth LLC bought a new stake in United Therapeutics during the 1st quarter valued at about $32,000. Finally, WealthCollab LLC raised its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Director Tommy G. Thompson sold 910 shares but still holds 8,480 shares (~$4.25M), signaling continued insider alignment with shareholders. SEC Filing — Thompson Sale
• Neutral Sentiment: All transactions were disclosed via SEC filings and covered by financial sites, providing transparency; investors should check the filings for whether sales were part of pre-set programs (e.g., 10b5-1) that reduce interpretive weight. SEC Filings
• Negative Sentiment: CEO Martine A. Rothblatt sold a total of 6,000 shares across Dec. 17 and Dec. 19 at ~ $501–$507, leaving her with only 130 shares — a ~94%+ reduction in reported ownership; that sharp drop can be read as a meaningful negative signal to some investors. SEC Filing — Rothblatt Sales
• Negative Sentiment: Additional senior insider sales: CFO and COO transactions reported (CFO ~$1.74M; COO ~$11.17M), increasing the volume and scope of executive selling within days — a likely near-term headwind for sentiment absent an explanatory disclosure. ABN: CEO Sale Coverage ABN: CFO Sale Coverage ABN: COO Sale Coverage

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.